Company Information
CIN
Status
Date of Incorporation
19 September 2005
State / ROC
Vijayawada / ROC Vijayawada
Last Balance Sheet
31 March 2023
Last Annual Meeting
14 July 2023
Paid Up Capital
1,077,931,716
Authorised Capital
1,110,000,000
Directors
Charles Robert Kaye
Director/Designated Partner
about 2 years ago
about 2 years ago
Venugopala Rao Malempati
Director/Designated Partner
over 2 years ago
over 2 years ago
Ravindranath Kancherla
Director/Designated Partner
over 2 years ago
over 2 years ago
Venkateswar Reddy Gogireddy
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Rajesh Koshy Chandy
Director/Designated Partner
over 9 years ago
over 9 years ago
Aruna Rajendra Bhinge
Director/Designated Partner
over 9 years ago
over 9 years ago
Rajesh Kumar Dugar
Director
about 13 years ago
about 13 years ago
Venkata Ravi Kumar Vantaram
Director/Designated Partner
about 19 years ago
about 19 years ago
Chava Satyanarayana
Director/Designated Partner
almost 20 years ago
almost 20 years ago
Past Directors
Venkata Lakshmana Rao Chunduru
Additional Director
over 7 years ago
over 7 years ago
Chandrakanth Chereddi
Whole Time Director
over 9 years ago
over 9 years ago
Conner Town Mulvee
Director
almost 10 years ago
almost 10 years ago
Brian Thomas Regan
Director
about 13 years ago
about 13 years ago
Robert Mark Weisskoff
Director
about 13 years ago
about 13 years ago
Francis Jackson Wright
Additional Director
almost 14 years ago
almost 14 years ago
Amal Ganguli
Additional Director
over 18 years ago
over 18 years ago
Nagarani Chava
Director
about 20 years ago
about 20 years ago
Patents
ABSTRACT
NOVEL POLYMORPHS OF DOLUTEGRAVIR AND SALTS THEREOF
The present invention relates to novel crystalline forms of dolutegravir, process for its preparation and pharmaceutical composition comprising them.
ABSTRACT:
The present invention generally relates to crystalline forms of Lumacaftor, processes for its preparation and pharmaceutical compositions thereof. The present invention also relates to an improved process for preparation of Lumacaftor.
The present invention relates to a process tor the preparation of disodium salt of pyrroloquinoline quinone. Also relates to novel polymorphic form of pyrroloquinoline quinone disodium salt and process for its preparation.
The present invention relates to a process for the preparation of carbamoylpyridone HIV integrase inhibitors and pharmaceutically acceptable salts thereof. The present invention specifically relates to a process for the preparation of carbamoylpyridone HIV integrase inhibitors such as dolutegravir, cabotegravir and ...
The present invention generally relates to novelsolid forms of lumacaftor, including amorphous form, solvates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same and to their use in therapy.
The present invention relates to solid forms of empagliflozin, in particular empagliflozin co-crystals, solvates and/or their polymorphs, processes for their preparation and a pharmaceutical composition containing the same.
Methods for particle size reduction of Pirfenidone.
The present invention provides the process for particle size reduction of pirfenidone by wet
milling techniques selected from colloid mill, ultrasonicator or high speed homogenizer.
A process for preparing 0- ketoester of formula (m) comprises; (a)condensing alkyl 3-formylbenzoate with 7-Chloroquinaldine to give alkyl 3-[((7-chloro-2-quinolinyl) ethenyl)] benzoate; and (b) reacting alkyl 3-[((7-chloro-2-quinolinyl) ethenyl)] benzoate with an alkyl ester in presence of metal hydride/metal alkoxi...
The present invention provides solid forms of SGLT2 inhibitors, to processes for their preparation and their use in the purification of SGLT2 inhibitors and also provided pharmaceutical compositions comprising them and their use in therapy.
ABSTRACT
PROCESS FOR PREPARATION OF CHLORANTRANILIPROLE OR A SALT THEREOF
The present invention generally relates to a process for preparation of chlorantraniliprole or a salt thereof by reaction of formula II with methyl amine, wherein “R” is selected from straight or branched chain C1-6 alkyl group.
Fo...
ABSTRACT
AN IMPROVED PROCESS FOR PREPARATION OF CHLORANTRANILIPROLE OR A SALT THEREOF
The present invention generally relates to a process for preparation of chlorantraniliprole or a salt thereof. Further, the present invention relates to an improved process for preparation of intermediate of chlorantranilipro...
ABSTRACT
“PROCESSES FOR PURIFICATION OF BICTEGRAVIR INTERMEDIATES”
The present invention generally relates to a process for purification of (2R,5S,13aR)-8-methoxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxylic acid of Formula I and (2R,5S,13aR...
ABSTRACT
PROCESS FOR THE PREPARATION OF AMORPHOUS CANAGLIFLOZIN SUBSTANTIALLY FREE OF HYDROPEROXIDE IMPURITY
The present invention provides process for the preparation of amorphous canagliflozin substantially free of hydroperoxide impurity. The present invention also provides pharmaceutical compositions compri...
The present invention relates to granules containing pirfenidone and a sugar alcohol, and, furthermore, to the use of the granules for the preparation of an immediate-release tablet or capsule.
ABSTRACT
AN IMPROVED PROCESS FOR 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL) ANILINE
The present invention relates to an improved process for the preparation of 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl) aniline of Formula (I).
ABSTRACT
PROCESS FOR PREPARATION OF 2-AMINO-5-HYDROXY PROPIOPHENONE
The present invention relates to a process for preparation of 2-Amino-5-hydroxy propiophenone, a key intermediate for the synthesis of camptothecin analogs including 7-Ethyl-10-hydroxycamptothecin (SN-38).
ABSTRACT
NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR
The present invention generally relates to processes for preparation of Tezacaftor and pharmaceutical composition comprising the same. The present invention also encompasses novel intermediates of tezacaftor, processes for its preparation and use of said i...
ABSTRACT
POLYMORPHIC FORMS OF VENETOCLAX AND ITS PREPARATION THEREOF
The present invention provides novel crystalline polymorphic forms of venetoclax and its processes for preparation thereof. The present invention also relates to processes for preparation of amorphous form of venetoclax and pharmaceutical com...
ABSTRACT
CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
The present invention relates to novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition comprising the same.
...
The present invention relates to a process for preparation of dolutegravir intermediate compound of formula V, wherein R represents alkyl, aryl or aralkyl group;
Formula V
The present invention generally relates to an improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof and preparation thereof. The present invention also relates to crystalline forms of monophenyl PMPA an important intermediate of tenofovir alafenamide and their pre...
The present invention generally relates to a process for preparation of 9-halo-3-(2-haloacetyl)- 10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one of Formula I, which is an intermediate in the preparation of Hepatitis C Virus (HCV) inhibitors.
ABSTRACT
The present invention relates to stable pharmaceutical composition of canagliflozin comprises one diluent, one disintegrant and one or more pharmaceutically acceptable excipients and also process for preparing the composition.
The present invention generally relates to an improved process for preparation of velpatasvir or a pharmaceutically acceptable salt thereof of Formula I.
ABSTRACT
METHOD FOR PREPARATION OF PYRAZOLE-CARBOXYLATE INTERMEDIATES
The present invention generally relates to an improved process for preparation of pyrazole-carboxylate intermediate of Formula II, an intermediate for preparation of certain anthranilamide compounds, for example chlorantraniliprole and cyantrani...
The present invention relates to novel polymorph of eluxadoline namely Form A. The present invention also relates to novel solvates of eluxadoline and process for the preparation and use thereof in the preparation of eluxadoline Form Aand its pharmaceutical composition comprising the same.
“An improved process for preparation of lopinavir and its intermediates thereof”
The present invention generally relates to an improved process for preparation of lopinavir
and its intermediates through formation of tartrate salt of compound of Formula III.
N
NH2
OH
Formula III
ABSTRACT
A PROCESS FOR THE PREPARATION OF PALBOCICLIB
The present invention relates to a process for the preparation of palbociclib, especially a process for the preparation of palbociclib having specific surface area greater than 2 m2/g.
ABSTRACT
A PROCESS FOR PURIFICATION OF PROTECTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES
The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts the...
ABSTRACT
“POLYMORPHIC FORMS OF APALUTAMIDE AND ITS PREPARATION THEREOF”
The present invention relates to novel crystalline polymorphic forms of apalutamide. The present invention also relates to processes for preparation of amorphous form of apalutamide and pharmaceutical composition containing the same.
...
ABSTRACT
PURIFICATION METHOD OF CARFILZOMIB
The present invention relates to a process for purification of carfilzomibfree from its impurities using preparative high performance liquid chromatography (prep-HPLC).
ABSTRACT
“PROCESS AND POLYMORPHIC FORMS OF BICTEGRAVIR AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS OR CO-CRYSTALS THEREOF”
The present invention generally relates to polymorphic forms of bictegravir, its salts, co-crystals, solvates or hydrates thereof and process for the preparation of the same and also relates...
ABSTRACT
PURIFICATION METHOD OF CABAZITAXEL
The present invention relates to a process for purification of cabazitaxel free from its impurities using preparative high performance liquid chromatography (HPLC).
The present invention relates to stable amorphous form of sacubitril valsartan trisodium complex and its solid dispersion compounds, processes for their preparation and pharmaceutical composition comprising the same. The present invention also relates to an improved process for the preparation of sacubitril sodium a...
ABSTRACT
SOLID FORMS OF TEZACAFTOR, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
The present invention relates to solid forms of Tezacaftor, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the sa...
ABSTRACT
ORAL FILM OF HIV DRUGS
The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retrovi...
The present invention relates to process for the preparation of Empagliflozin or its co- crystals, solvates and/or polymorphs thereof. The present invention also relates to novel intermediates used therein, and process for the preparation thereof. The present invention further relates to process for preparation of a...
The present invention relates to stable amorphous form of sacubitril valsartan trisodium complex and its solid dispersion compounds, processes for their preparation and pharmaceutical composition comprising the same. The present invention also relates to an improved process for the preparation of sacubitril sod...
ABSTRACT
AN IMPROVED PROCESS FOR PREPARATION OF 2-AMINO-5-CHLORO-N-3-DIMETHYL BENZAMIDE
The present invention generally relates to an improved one-pot process for preparation of 2-amino-5-chloro-N-3-dimethylbenzamide of Formula IV, an intermediate for preparation of chlorantraniliprole.
Formula IV
...
ABSTRACT
AN IMPROVED PROCESS FOR PREPARATION OF 2-AMINO-5-CHLORO-N-3-DIMETHYL BENZAMIDE
The present invention generally relates to an improved one-pot process for preparation of 2-amino-5-chloro-N-3-dimethylbenzamide of Formula IV, an intermediate for preparation of chlorantraniliprole.
Formula IV
...
ABSTRACT
PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR
The present invention generally relates to crystalline forms of Lumacaftor, processes for its preparation and pharmaceutical compositions thereof. The present invention also relates to an improved process for preparation of Lumacaftor.
An Improved Process For The Preparation Of Trigonelline Or Pharmaceutically Acceptable Salts Thereof
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF TRIGONELLINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention generally relates to an improved process for the preparation of Trigonelline or pharmaceutically acceptable salts thereof and to processes for its purification.
...
ABSTRACT
PROCESS FOR PREPARATION OF CABOTEGRAVIR
The present invention relates to a process for preparation cabotegravir and its intermediates thereof. The present invention further relates to a process for purification cabotegravir and its pharmaceutical composition thereof.
ABSTRACT
PURIFICATION OF (2R,5S,13AR)-8-METHOXY-7,9-DIOXO-N-[(2,4,6-TRIFLUOROPHENYL)METHYL)]-2,3,4,5,7,9,13,13A-OCTAHYDRO2,5-METHANOPYRIDO-[1’,2':4,5]PYRAZINO[2,1-B][1,3]-OXAZEPINE-10-CARBOXAMIDE
The present invention generally relates to a process for purification of (2R,5S,13aR)-8-methoxy7,9-dioxo-N-[(2,4,6-trif...
ABSTRACT
“A PROCESS FOR PURIFICATION OF VENETOCLAX OR ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF”
The present invention relates to a process for purification of venetoclax or its pharmaceutically acceptable salt thereof and pharmaceutical composition containing the same.
ABSTRACT
A PROCESS FOR PURIFICATION OF POLYCYCLIC-PYRIDONE COMPOUNDS
The present invention generally relates to a process for purification of polycyclic-pyridone compounds, specifically compound of Formula XI, an intermediate for preparation of cabotegravir.
Formula XI
wherein “Y” -represents hydrogen, c...
ABSTRACT
“A NOVEL INTERMEDIATE OF DOLUTEGRAVIR AND A METHOD OF PREPARATION THEREOF”
The present invention relates to a process for preparation of dolutegravir intermediate compound of formula VII, wherein R represents alkyl, aryl or aralkyl group; R1 and R2 independently represent an alkyl.
...
The present invention relates to a process for preparation of dolutegravir intermediate compound of formula IV, wherein R represents alkyl, aryl or aralkyl group.
Formula IV
ABSTRACT
MONOLAYER TABLET OF DOLUTEGRAVIR AND LAMIVUDINE
The present invention relates to a monolayer tablet composition comprising a) Dolutegravir and b) lamivudine and one or more pharmaceutically acceptable excipients. Specifically present invention relates to a monolayer tablet comprising Dolutegravir and ...
ABSTRACT
POLYMORPHIC FORMS OF MOLNUPIRAVIR AND ITS PREPARATION THEREOF
The present invention relates to solid forms of molnupiravir, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same.
ABSTRACT
A PROCESS FOR PREPARATION OF CABOTEGRAVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention generally relates to a process for preparation of cabotegravir or its pharmaceutically acceptable salts thereof using a stable compound of Formula II; wherein R1 and R2 represents C1-6 a...
ABSTRACT
ORAL FILM OF CFTR MODULATOR(S)
The present invention provides oral film(s) of Cystic fibrosis transmembrane conductance regulator (CFTR) modulator(s) or a pharmaceutically acceptable salt thereof. Further the present invention provides composition and process for preparing oral film(s) comprising Cyst...
ABSTRACT
PROCESS FOR PREPARATION OF POLYMORPHIC FORM OF CABOTEGRAVIR SODIUM
The present invention generally relates to a process for preparation of polymorphic form of cabotegravir sodium and pharmaceutical composition thereof. Specifically, the present invention relates to a process for preparation of crystal...
ABSTRACT
ORAL FILMS OF ANTI-EMETIC DRUGS
The present invention relates to new oral dosage forms of Anti-emetic drugs and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically the present invention provides compositions and process for pr...
ABSTRACT
ORAL FILMS OF ANTIPRURITIC DRUGS
The present invention relates to new oral dosage forms of Antipruritic drug(s) and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically the present invention provides compositions and process fo...
ABSTRACT
ORAL FILMS OF ANTI-PARASITIC DRUGS
The present invention relates to new oral dosage forms of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically the present invention provides compositions and process ...
ABSTRACT
ORAL FILMS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
The present invention relates to new oral dosage forms of Non-steroidal anti-inflammatory drugs (NSAIDs) and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically the present i...
ABSTRACT
ORAL FILM OF HIV DRUGS
The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retrovi...
ABSTRACT
ORAL FILM OF HIV DRUGS
The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retrovi...
ABSTRACT
ORAL FILM OF HIV DRUGS
The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retrovi...
ABSTRACT
ORAL FILM OF HIV DRUGS
The present invention provides oral film of HIV/Anti-retroviral drugs and its pharmaceutically acceptable salt thereof, which is useful for the treatment of HIV infections. Further the present invention provides composition and process for preparing oral film of HIV/Anti-retrovi...
ABSTRACT
“PROCESS FOR PREPARATION OF AZABICYCLO [3.1.0] HEXANE INTERMEDIATES”
The present invention generally relates to a process for preparation of azabicyclo [3.1.0] hexane intermediate of Formula-I, an intermediate for preparation of certain antiviral compounds for example boceprevir and nirmatrelvir.
...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR ALAFENAMIDE MONOFUMARATE
The present generally relates to an improved process for the preparation of tenofovir alafenamide monofumarate by treating tenofovir alafenamide with fumaric acid having particle size less than 120 µm.
...
ABSTRACT
AN IMPROVED PROCESS FOR PREPARATION OF CYANTRANILIPROLE OR A SALT THEREOF
The present invention relates to process for preparation of 2-amino-5-cyano-N, 3-dimethyl benzamide of Formula V, an intermediate for preparation of cyantraniliprole or a salt thereof. The present invention further relates to an...
ABSTRACT
A PROCESS FOR PURIFICATION OF SITAGLIPTIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to an improved process for the preparation of pure Sitagliptin or pharmaceutically acceptable salts thereof, particularly sitagliptin hydrochloride or sitagliptin phosphate substantiall...
Registered Trademarks
[Class : 5] Pharmaceuticals, Medical, Dietetic Food And Substances Adapted For Medical Or Veterinary Use.
[Class : 5] Nutraceuticals & Dietary Supplements
[Class : 5] Pharmaceutical And Medicinal Preparations
View +56 more Brands for Laurus Labs Limited.
Charges
14 February 2019
The Hongkong And Shanghai Banking Corporation Limited
177 Crore
15 October 2018
Citibank N. A.
40 Crore
30 December 2017
Andhra Bank
23 Crore
23 August 2017
Hdfc Bank Limited
100 Crore
19 March 2015
The Hongkong And Shanghai Banking Corporation Limited
2 Crore
17 September 2014
State Bank Of India
1,213 Crore
22 October 2007
State Bank Of India
94 Crore
10 March 2016
The Hongkong And Shanghai Banking Corporation Limited
50 Crore
21 July 2012
Bank Of Bahrain & Kuwait B.s.c
28 Crore
06 September 2013
Icici Bank Limited
22 Crore
16 December 2013
Export-import Bank Of India
49 Crore
30 January 2013
Export-import Bank Of India
100 Crore
31 December 2014
Punjab National Bank
145 Crore
09 July 2014
Idbi Bank Limited
50 Crore
07 March 2014
State Bank Of Hyderabad
45 Crore
15 July 2013
Citibank N. A.
25 Crore
09 March 2009
State Bank Of Hyderabad
100 Crore
31 October 2011
Bank Of Bahrain & Kuwait B.s.c
32 Crore
10 October 2011
Icici Bank Limited
43 Crore
24 June 2014
Hdfc Bank Limited
50 Crore
30 May 2014
The Ratnakar Bank Limited
50 Crore
06 August 2012
Ing Vysya Bank Limited
122 Crore
10 June 2014
The Hongkong And Shanghai Banking Corporation Limited
60 Crore
22 March 2010
Punjab National Bank
20 Crore
23 June 2011
Bank Of Bahrain & Kuwait B.s.c.
15 Crore
01 July 2010
Tata Capital Limited
10 Crore
11 March 2011
Sbi Global Factors Limited
30 Crore
16 December 2009
State Bank Of Hyderabad
5 Crore
27 October 2020
The Hongkong And Shanghai Banking Corporation Limited
150 Crore
04 September 2020
State Bank Of India
200 Crore
14 March 2023
Axis Bank Limited
0
23 June 2011
Bank Of Bahrain & Kuwait B.s.c.
0
31 December 2014
Punjab National Bank
0
19 March 2015
The Hongkong And Shanghai Banking Corporation Limited
0
09 July 2014
Idbi Bank Limited
0
24 June 2014
Hdfc Bank Limited
0
10 June 2014
The Hongkong And Shanghai Banking Corporation Limited
0
30 May 2014
The Ratnakar Bank Limited
0
07 March 2014
State Bank Of Hyderabad
0
16 December 2013
Export-import Bank Of India
0
06 September 2013
Icici Bank Limited
0
15 July 2013
Citibank N. A.
0
30 January 2013
Export-import Bank Of India
0
09 March 2009
State Bank Of Hyderabad
0
16 December 2009
State Bank Of Hyderabad
0
22 March 2010
Punjab National Bank
0
01 July 2010
Tata Capital Limited
0
11 March 2011
Sbi Global Factors Limited
0
10 October 2011
Icici Bank Limited
0
31 October 2011
Bank Of Bahrain & Kuwait B.s.c
0
21 July 2012
Bank Of Bahrain & Kuwait B.s.c
0
06 August 2012
Ing Vysya Bank Limited
0
25 January 2022
Hdfc Bank Limited
0
15 October 2018
Others
0
14 February 2019
The Hongkong And Shanghai Banking Corporation Limited
0
04 September 2020
State Bank Of India
0
27 October 2020
The Hongkong And Shanghai Banking Corporation Limited
0
17 September 2014
State Bank Of India
0
23 August 2017
Hdfc Bank Limited
0
21 April 2022
Others
0
16 May 2022
Sbicap Trustee Company Limited
0
22 October 2007
Others
0
10 March 2016
The Hongkong And Shanghai Banking Corporation Limited
0
30 December 2017
Others
0
06 December 2023
Hdfc Bank Limited
0
14 March 2023
Axis Bank Limited
0
23 June 2011
Bank Of Bahrain & Kuwait B.s.c.
0
31 December 2014
Punjab National Bank
0
19 March 2015
The Hongkong And Shanghai Banking Corporation Limited
0
09 July 2014
Idbi Bank Limited
0
24 June 2014
Hdfc Bank Limited
0
10 June 2014
The Hongkong And Shanghai Banking Corporation Limited
0
30 May 2014
The Ratnakar Bank Limited
0
07 March 2014
State Bank Of Hyderabad
0
16 December 2013
Export-import Bank Of India
0
06 September 2013
Icici Bank Limited
0
15 July 2013
Citibank N. A.
0
30 January 2013
Export-import Bank Of India
0
09 March 2009
State Bank Of Hyderabad
0
16 December 2009
State Bank Of Hyderabad
0
22 March 2010
Punjab National Bank
0
01 July 2010
Tata Capital Limited
0
11 March 2011
Sbi Global Factors Limited
0
10 October 2011
Icici Bank Limited
0
31 October 2011
Bank Of Bahrain & Kuwait B.s.c
0
21 July 2012
Bank Of Bahrain & Kuwait B.s.c
0
06 August 2012
Ing Vysya Bank Limited
0
25 January 2022
Hdfc Bank Limited
0
15 October 2018
Others
0
14 February 2019
The Hongkong And Shanghai Banking Corporation Limited
0
04 September 2020
State Bank Of India
0
27 October 2020
The Hongkong And Shanghai Banking Corporation Limited
0
17 September 2014
State Bank Of India
0
23 August 2017
Hdfc Bank Limited
0
21 April 2022
Others
0
16 May 2022
Sbicap Trustee Company Limited
0
22 October 2007
Others
0
10 March 2016
The Hongkong And Shanghai Banking Corporation Limited
0
30 December 2017
Others
0
